Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
Takeuchi T, Takahashi Y, Kawaguchi S, Ota K, Harada S, Kojima Y, Sakamoto H, Kuramoto T, Kojima K, Sanomura M, Hoshimoto M, Higashino T, Itabashi T, Takada K, Sakaguchi M, Tominaga K, Kusano M, Higuchi K. Takeuchi T, et al. Among authors: tominaga k. J Gastroenterol Hepatol. 2018 Mar;33(3):623-630. doi: 10.1111/jgh.13970. J Gastroenterol Hepatol. 2018. PMID: 28865098 Clinical Trial.
A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study.
Tominaga K, Kato M, Takeda H, Shimoyama Y, Umegaki E, Iwakiri R, Furuta K, Sakurai K, Odaka T, Kusunoki H, Nagahara A, Iwakiri K, Furuta T, Murakami K, Miwa H, Kinoshita Y, Haruma K, Takahashi S, Watanabe S, Higuchi K, Kusano M, Fujimoto K, Arakawa T; G-PRIDE Study Group. Tominaga K, et al. J Gastroenterol. 2014 Oct;49(10):1392-405. doi: 10.1007/s00535-013-0896-9. Epub 2014 Feb 18. J Gastroenterol. 2014. PMID: 24535455 Clinical Trial.
Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito.
Sakata Y, Tominaga K, Kato M, Takeda H, Shimoyama Y, Takeuchi T, Iwakiri R, Furuta K, Sakurai K, Odaka T, Kusunoki H, Nagahara A, Iwakiri K, Furuta T, Murakami K, Miwa H, Kinoshita Y, Haruma K, Takahashi S, Watanabe S, Higuchi K, Fujimoto K, Kusano M, Arakawa T; G-PRIDE study group. Sakata Y, et al. Among authors: tominaga k. BMC Gastroenterol. 2014 Jul 2;14:116. doi: 10.1186/1471-230X-14-116. BMC Gastroenterol. 2014. PMID: 24990161 Free PMC article. Clinical Trial.
Efficacy and safety of Helicobacter pylori eradication therapy immediately after endoscopic submucosal dissection.
Takahashi Y, Takeuchi T, Kojima Y, Nagami Y, Ominami M, Uedo N, Hamada K, Suzuki H, Oda I, Miyaoka Y, Yamanouchi S, Tokioka S, Tomatsuri N, Yoshida N, Naito Y, Nonaka T, Kodashima S, Ogata S, Hongo Y, Oshima T, Li Z, Shibagaki K, Oikawa T, Tominaga K, Higuchi K. Takahashi Y, et al. Among authors: tominaga k. J Gastroenterol Hepatol. 2018 Jul;33(7):1341-1346. doi: 10.1111/jgh.14073. Epub 2018 Mar 7. J Gastroenterol Hepatol. 2018. PMID: 29265496 Clinical Trial.
Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
Ozaki H, Harada S, Takeuchi T, Kawaguchi S, Takahashi Y, Kojima Y, Ota K, Hongo Y, Ashida K, Sakaguchi M, Tokioka S, Sakamoto H, Furuta T, Tominaga K, Higuchi K. Ozaki H, et al. Among authors: tominaga k. Digestion. 2018;97(3):212-218. doi: 10.1159/000485097. Epub 2018 Jan 31. Digestion. 2018. PMID: 29393194 Clinical Trial.
1,359 results